Inari Medical stock soars on Stryker acquisition

Stryker Corporation, a leading entity in the medical technology sector, has entered into an agreement to acquire Inari Medical for $4.9 billion. The acquisition involves purchasing all of Inari’s outstanding shares at $80 each. This deal marks a strategic move by Stryker to broaden its portfolio with Inari's expertise in mechanical thrombectomy solutions for peripheral vascular diseases. Inari specializes in treatments for conditions like deep vein thrombosis and pulmonary embolism, which complement Stryker’s Neurovascular offerings. The transaction will proceed as a tender offer and is expected to complete in early 2025, pending customary conditions. Both companies aim to enhance innovations and solutions in venous thromboembolism, a condition affecting millions annually.